Chemical development of the vasopressin receptor 2 antagonist SR-121463*

István Hermecz†,^{1} Andrea Sánta-Csutor^{2}, Csaba Gönczi^{2}, Gergely Héja^{2}, Éva Csikós^{2}, Kálmán Simon^{3}, Ágota Smelkó-Esek^{3}, and Benjámin Podányi^{3}

^{1}Preclinical Development, ^{2}Synthetic Development, ^{3}Preclinical Analytical Development Laboratories; Chinoin Pharmaceutical and Chemical Works Ltd., H-1045 Budapest, Tó u. 1-5, Hungary

Abstract: A facile convergent total synthesis of the selective, potent, and orally active V₂ non-peptide antagonist, SR-121463, was developed by modification of the discovery route. One of the late intermediates, the sulfonyl chloride 1, was synthesized from 3-hydroxybenzoic acid (19) by regioselective sulfonation, O-methylation and amidation in four steps. Another late intermediate, indolin-2-one 2, was prepared from p-phenetidine (8) through the indolin-2-one 16, where the cyclohexanone moiety of 27 was introduced into the active 3-methylene group of 16 by sequential transformation using methyl acrylate and KOtBu. After formation of the cyclic ketal moiety of 13, its ring-opening was achieved by using NaBH₄ in the presence of CCl₃COOH. The morpholino group in 2 was introduced in accordance with the discovery approach, starting from the 2-hydroxyethoxy derivative 14 through the tosylxyoxy derivative 15 with morpholine in a one-pot reaction. In this way, the indolin-2-one 2 was synthesized from 8 in six steps. Finally, acylation of the indolin-2-one 2 was achieved with the sulfonyl chloride 1 in the presence of KOtBu in dimethyl sulfoxide (DMSO) at room temperature. This synthetic route proved to be applicable for the large-scale synthesis of SR-121463.

INTRODUCTION

The key elements of drug discovery and development are biological target selection and lead compound selection in the early pharmaceutical research, and preclinical and clinical evaluation of a drug candidate in the late pharmaceutical R&D activities (Fig. 1). Chemists play a significant role as medicinal chemists in the early stages, and as process chemists in the late stage of drug research. In 1999, at the

![Fig. 1 Main activities in drug discovery and drug development.](image-url)
First Italian-Hungarian-Polish Joint Meeting on Medicinal Chemistry at Giardini-Naxos, Sicily, we discussed the content and applications of the means of medicinal chemistry in the case of prolyl endopeptidase inhibitors [1,2].

On this occasion, we discuss the next step, the process chemistry activities as the initial stages in the preclinical development of a drug candidate. We present here results on the process research of a non-peptide antagonist (SR-121463) of arginine vasopressin receptor 2.

ARGinine VASOPRESSin RECEPTORS AND THEIR NON-PEPTIDE INHIBITORs

Arginine vasopressin (AVP) is a cyclic nonapeptide (Fig. 2) with distinct biological functions [3]. Its primary role involves regulation of the renal and cardiovascular functions [4]. To date, 3 subtypes of AVP receptors have been identified and cloned [5,6]: the V₁-vascular receptor [5], the V₂-renal receptor [6], and the V₁b or V₃-pituitary receptor [7,8]; however, their crystallographic structures remain to be established. They belong in the G protein-coupled superfamily [9]. Recent reports on AVP agonistic activity suggest the presence of an as yet uncharacterized new AVP receptor [10,11]. Depending on the second messenger involved, this could be classified as a V₁c or V₂b receptor.

![Fig. 2 Arginine vasopressin (AVP).](image)

While potent and selective V₁a and V₂ non-peptide antagonists have been developed, there is still a need for potent and selective V₁b non-peptide antagonists. Potential therapeutic uses of AVP receptor antagonists include the blockade of V₁-vascular receptors in arterial hypertension, congestive heart failure (CHF), and peripheral vascular diseases; the blockade of V₂-renal receptors in the syndrome of inappropriate AVP secretion, CHF, liver cirrhosis, nephrotic syndrome, and any state of excessive retention of free water and subsequent hyponatremia; the blockade of V₁b (V₃)-pituitary receptors in adrenocorticotropicin (ACTH)-secreting tumors [12].

The first selective non-peptide V₁a antagonist, OPC-21268, a tetrahydroquinolinone derivative, was developed by Otsuka Pharmaceuticals [13] (Fig. 3). Unfortunately, marked species differences have been reported; the affinity of OPC-21268 for the human V₁a receptors is rather weak [14,15], whereas high affinity for the rat liver receptor has been confirmed. An alternative non-peptide V₁a receptor ligand, SR-49059, an indoline derivative, was developed by Sanofi researchers [16]. This molecule displays high affinity, selectivity, and efficacy at V₁a receptors in human tissues where OPC-21268 is

![Fig. 3 Non-peptide inhibitors of AVP receptor 1a.](image)
almost ineffective. SR-49059 has entered clinical trials for hypertension and CHF, and represents an important new pharmacological tool.

As yet, there has been no report on non-peptide V$_{1b}$-receptor antagonists, but very potent and selective V$_2$ non-peptide antagonists have been developed (Fig. 4), which are the congeners of previously discussed V$_{1a}$ antagonists (Fig. 3). Otsuka Pharmaceuticals developed a benzazepine derivative, the orally bioavailable OPC-31260 [17,18], which proved to be active in humans [19]. The Sanofi group also reported an orally bioavailable V$_2$ antagonist, SR-121463 [20]. VPA-985 is another specific and selective V$_2$ antagonist, developed by Wyeth-Ayerst Research; it is currently being evaluated in clinical trials [21]. Yamanouchi Pharmaceutical also recently reported an orally effective, dual V$_{1a}$/V$_2$ receptor antagonist, YM-087. The V$_2$ receptor blockade is more pronounced than the V$_{1a}$ receptor blockade [22,23].

The AVP V$_2$ receptor has been defined as the renal adenylate cyclase-coupled receptor involved in the antidiuretic effect of AVP [24]. AVP stimulation of the V$_2$ receptors on kidney collecting duct cells causes the migration of aquaporin 2 water channels to the cell surface, promoting water reuptake. The V$_2$ receptor inhibitors shut off cAMP and aquaporin 2 production, so that water is released as urine, with little effect on the urinary sodium and potassium excretion, which is at variance with classical natriuretic agents. The term “aquaretics” has been coined to describe this class of agents [25].

We present here an account of our results on the process research performed to develop a facile total synthesis of SR-121463 suitable for large-scale operation.

**DISCOVERY ROUTE FOR THE SYNTHESIS OF SR-121463**

The discovery route for synthesis of SR-121463 is depicted in Schemes 1–4 [26]. The final step in the synthesis involves the acylation of the N(1) nitrogen of the indolin-2-one 2 with the sulfonyl chloride 1 in tetrahydrofuran (THF) between –60 and –20 °C in the presence of KOtBu to provide SR-121463 (Scheme 1).

© 2001 IUPAC, Pure and Applied Chemistry 73, 1401–1409
In the synthesis of the sulfonyl chloride 1, medicinal chemists started from 3-methoxy-4-nitrobenzoic acid (3) (Scheme 2). First, the carboxylic acid chloride 4 was formed by treatment of 3 with SOCl₂, after which 4 was reacted with tBuNH₂ at –40 °C to give the benzamide 5. The nitro group of the benzamide 5 was reduced to an amino group by a hydrogen-transfer reaction using cyclohexene over Pd/C as catalyst. The subsequent diazotization of N-(tert-butyl)-4-amino-3-methoxybenzamide (6) with NaNO₂ in acidic medium yielded the diazonium salt 7. The diazonium moiety of 7 was replaced by a sulfonyl chloride group by treatment with liquid SO₂ at –25 °C, to afford 1.

Scheme 2 Discovery route for the synthesis of the sulfonyl chloride 1.

In the synthesis of the indolin-2-one 2, medicinal chemists started from p-phenetidine (8), which was diazotized in concentrated HCl with NaNO₂, and the diazonium group was subsequently reduced to a hydrazine group with SnCl₂ (Scheme 3). The arylhydrazine 9 was reacted with a mixed anhydride, formed from the sodium cyclohexylcarboxylate derivative 11 with isobutyl chloroformate in THF in the presence of NEt₃. The sodium cyclohexylcarboxylate derivative 11 was prepared from the expensive ethyl 4-hydroxy-cyclohexylcarboxylate. Its oxidation with pyridinium chlorochromate on basic alumina in EtOAc afforded the cyclohexanone 10, which was reacted with ethylene glycol in the presence of

Scheme 3 Discovery route for spiroindolin-2-one 13.
$p$-toluene sulfonic acid (PTSA), followed by the hydrolysis of ester group with NaOH in EtOH to yield sodium salt 11. Fischer indolization of the cyclohexylcarbohydrazide 12 in the Brunner reaction [27,28], with formation of the lithium salt of 12 with BuLi in THF at $-70 \, ^\circ\text{C}$, followed by heating of the lithium salt of 12 in tetraline at 180 °C, yielded 3-spiro(4,4-ethylenedioxycyclohexane)indolin-2-one 13.

The cyclic ketal moiety of compound 13 was opened by treatment with Zn(BH$_4$)$_2$ in the presence of Me$_3$SiCl to afford a 85:15 mixture of cis 14 and trans (not shown) isomers of the 2-hydroxyethoxy derivative (Scheme 4). Pure 14 could be obtained by crystallization from toluene. The hydroxy group of the 2-hydroxyethoxy derivative 14 was acylated with tosyl chloride, and the toslyloxy group of 15 was then replaced by a morpholino group by reaction with morpholine in the presence of Na$_2$CO$_3$ to yield the desired indolin-2-one 2.

The main drawbacks of the discovery route are as follows:

- introduction of the sulfonyl chloride group through the diazonium moiety of 7 with liquid SO$_2$
- preparation of the arylhydrazine 9 from $p$-phenetidine (8) through a diazonium salt and its reduction with SnCl$_2$
- use of the Brunner modification of Fischer indolization, lithium salt formation of 12 with BuLi at $-70 \, ^\circ\text{C}$, change of solvent for tetraline, and heating at 180 °C
- use of Zn(BH$_4$)$_2$, which is moisture and air-sensitive, and should be freshly prepared [29]
- starting from commercially unavailable 3-methoxy-4-nitrobenzoic acid (3) and the expensive ethyl 4-hydroxyxycyclohexylcarboxylate

These drawbacks make this approach unattractive for large-scale operation.

**DEVELOPMENT ROUTE FOR SR-121463**

After a retrosynthetic analysis of SR-121463 (Scheme 5), we decided to use a 3-methoxy- or 3-hydroxybenzoic acid derivative as starting material for the synthesis of building block 1, and the 3-unsubstituted indolin-2-one 16 for the synthesis of building block 2.

First, we attempted the sulfonation of 3-methoxybenzoic acid (18) with concentrated H$_2$SO$_4$, but unfortunately this led to a complex reaction mixture (Scheme 6). Next, we adapted the work of Shah [30], starting from 3-hydroxybenzoic acid (19), but concentrated H$_2$SO$_4$ was used instead of H$_2$SO$_4$ containing 3% SO$_3$. In this case, only the desired sulfonic acid was formed and isolated as its potassium salt 20. The critical step was the regioselective methylation of 20, which could be achieved in excellent yield under phase-transfer conditions, when the pH of the reaction mixture was maintained above 11 by the slow simultaneous addition of a KOH solution and Me$_3$SO$_4$. The diaacyl chloride 22 was smoothly prepared from a potassium salt 21 with the Vielsmeier–Haack reagent at room temperature. When 22 was reacted with $t$BuNH$_2$ at room temperature, the diamide 23 was obtained. However,
decrease of the reaction temperature to below –5 °C resulted in the regioselective amidation of 22 to provide exclusively the sulfonyl chloride 1.

The indolin-2-one 16 was prepared by the method of Di Malta et al. [31]. Ethyl 2-chloro-2-(methylthio)-acetate, prepared in situ from ethyl 2-chloroacetate and Cl₂ in CH₂Cl₂ at –70 °C, was reacted with 8 in the presence of NEt₃, while the reaction temperature was allowed to increase from –70 °C to room temperature, to yield 5-ethoxy-3-(methylthio)indolin-2-one. Treatment of the 3-methylthio derivative with Raney Ni in iPrOH at 80 °C under nitrogen provided the 3-unsubstituted indolin-2-one 16.

We set out to introduce the cyclohexanone moiety into the active 3-methylene group of 16 by the Michael addition [32] of alkyl acrylate, followed by the Dieckmann condensation [33] of the diester 25, and then hydrolysis of the β-oxo ester 26 (Scheme 7). In the initial experiments, we used the acid-labile tetrahydropyranyl group [34] for protection of the NH in 16. The overall yield of 27 was low (∼20%), and accordingly we considered the use of alkyl acrylate not only as reagent, but also as protecting group. The alkoxy carbonyl group could be eliminated by an E1cB mechanism [35]. The addition of ethyl acrylates was carried out in DMSO in the presence of KOtBu. We isolated intermediates 24–26, and the hydrolysis and deprotection were performed separately. The application of methyl
acrylate gave a better yield than that with ethyl acrylate. Finally, we developed a sequential transformation [36] in which a 2-methoxy-carbonylethyl group was introduced into 16 at 40–50 °C with methyl acrylate in the presence of a catalytic amount of KOtBu; the reaction temperature was then increased to 50–60 °C, and another portion of KOtBu was added to the reaction mixture. The completion of the Michael addition and the subsequent Dieckmann condensation of the diester 25 were followed by means of thin-layer chromatography (TLC) investigations. After this, H2O was added to the reaction mixture, and the hydrolytic process and deprotection started at 75–80 °C. This one-pot reaction afforded compound 27 a yield of over 60%. The reaction of 27 with ethylene glycol in the presence of PTSA furnished the spiroindolin-2-one 13.

From this point, we applied the discovery route (Scheme 4), but we used NaBH3CN in the presence of BF3·Et2O instead of the Zn(BH4)2–Me3SiCl system, and we obtained an 85:15 mixture of cis 14 and trans 2-hydroxyethyl derivatives. When we carried out this reduction on a 25 mol scale in a closed system, special attention was paid to destruction of the liberated HCN. The roles of the Lewis acids (e.g., BF3) and Me3SiCl in this reduction are the coordination of one of the oxygens of the ketal moiety, and the formation of a ring-chain tautomer. In the ring tautomer, (Scheme 8) the oxonium species is involved in the reduction. The formation of the cis and trans isomers is governed by steric factors. The Lewis acid could be replaced by proton, when a strong acid such as CF3COOH or CCl3COOH, was applied, and NaBH4 could be used as reducing agent.

Scheme 7 Development route for the spiroindolin-2-one 13.

Scheme 8 Role of a Lewis acid in the ring opening of the dioxolane moiety.
We also introduced the morpholino group in a one-pot reaction. The hydroxy group in 14 was tosylated in pyridine, the reaction mixture was then diluted with EtOH and morpholine was added. After boiling for 1 h, the indolin-2-one 2 was obtained in good yield. Acylation of the indolin-2-one 2 with the sulfonyl chloride 1 was achieved at room temperature in the presence of KOrBu, with DMSO used as solvent instead of THF.

The elaborated synthetic route was applied without difficulty in large-scale operations and provided SR-121463 in good quality, containing less than 0.2% of the trans isomer. The overall yield of the discovery route (~0.2%) was increased to 9%.

REFERENCES


